Abstract Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval as…
Abstract Many psychiatric patients do not respond to conventional therapy. There is a vast effort to investigate possible mechanisms involved…
Abstract (1) Background: With the massive demand for the use and commercialization of medicinal cannabidiol (CBD) products, new randomized clinical…
Abstract Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on…
Abstract Cannabidiol (CBD) is a non-psychotomimetic constituent of the Cannabis plant, with potential therapeutic properties for many physical and neuropsychiatric…
Abstract Cannabidiol (CBD) is a non-intoxicating compound extracted from Cannabis sativa, showing antidepressant-like effects in different rodent models. However, inconsistent…
Abstract Question: Is cannabidiol (CBD) therapy capable of reducing emotional exhaustion and burnout symptoms among frontline health care professionals working…
Abstract Objective: To compare plasma concentrations of cannabidiol (CBD) following oral administration of two formulations of the drug (powder and…
Abstract Cannabidiol (CBD) is a phytocannabinoid with a broad-range of therapeutic potential in several conditions, including neurological (epilepsy, neurodegenerative diseases,…
Abstract Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid…